CHICAGO, July 20 (Reuters) - The U.S. government on Thursday said it has cut a deal with British drugmaker GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) to supply its influenza drug, Relenza, to states at a subsidized price. The move comes as governments around the world have begun building stockpiles of antiviral drugs in the event of a bird- flu pandemic.
